Haemonetics
181 hedge funds and large institutions have $2.22B invested in Haemonetics in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 79 increasing their positions, 54 reducing their positions, and 25 closing their positions.
200% more call options, than puts
Call options by funds: $9K | Put options by funds: $3K
46% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 54
5% more capital invested
Capital invested by funds: $2.11B → $2.22B (+$108M)
3.54% more ownership
Funds ownership: 101.53% → 105.07% (+3.5%)
9% less funds holding
Funds holding: 198 → 181 (-17)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
40% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$245M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$30.2M |
| 3 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$22.9M |
| 4 |
HM
HealthCor Management
New York
|
+$17.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$75.4M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$5.89M |
| 3 |
CCMH
Cornerstone Capital Management Holdings
New York
|
-$5.82M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.56M |
| 5 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$4.05M |
HAE Hedge Fund Activity: Q1 2017 in Review
181 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q1 2017, worth a combined $2.22B — up 5.1% from $2.11B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of HAE and 15 opened new positions — a net loss of 10 holders — while 54 trimmed existing stakes and 79 added.
The largest buyer was BlackRock, adding an estimated $245M. The largest seller was T. Rowe Price Associates, cutting an estimated $75.4M.
- 181 institutional investors held Haemonetics (HAE) as of Q1 2017, down from 198 in Q4 2016.
- Funds reported $2.22B of Haemonetics stock for Q1 2017, up 5.1% quarter-over-quarter.
- 15 funds opened new Haemonetics positions in Q1 2017 and 25 closed out, a net change of -10 holders.
- The largest Haemonetics buyer in Q1 2017 was BlackRock, an estimated $245M added.
- The largest Haemonetics seller in Q1 2017 was T. Rowe Price Associates, an estimated $75.4M sold.
Based on aggregated 13F filings for Q1 2017.